January 2026 in “Frontiers in Pharmacology” Wedelolactone may help treat inflammation, infections, cancer, bone loss, and organ damage.
5 citations
,
March 2020 in “Thoracic Cancer” CT-707 is effective and safe for treating certain Chinese lung cancer patients.
April 2023 in “The journal of investigative dermatology/Journal of investigative dermatology” Ritlecitinib significantly improves scalp hair regrowth in alopecia areata patients over time.
2 citations
,
January 1990 in “Leukemia & Lymphoma” The combination of mitoxantrone, etoposide, and prednisolone is effective for treating relapsed lymphoma with manageable side effects.
14 citations
,
August 2015 in “Endocrinology” The antibody 005-C04 blocks prolactin receptors, causing reversible infertility, impaired lactation, and hair regrowth in female mice.
September 2024 in “Drugs & Therapy Perspectives” Ritlecitinib effectively regrows hair in severe alopecia areata and is well tolerated.
January 2026 in “Zenodo (CERN European Organization for Nuclear Research)” LX-38 is a safer drug option for hair loss and prostate issues without hormonal side effects.
33 citations
,
May 2017 in “Journal of Clinical Oncology” ETC-159 was safe up to 30 mg, but no tumor shrinkage was seen.
1 citations
,
December 2024 in “Journal of Orthopaedic Research®” Aromoline and DRD4 are potential targets for osteoarthritis treatment.
5 citations
,
January 2024 in “Journal of Cancer” The treatment combination is effective and generally safe for lung cancer.
6 citations
,
March 2024 in “SKIN The Journal of Cutaneous Medicine” Ritlecitinib is effective for long-term treatment of severe alopecia areata.
January 2026 in “Zenodo (CERN European Organization for Nuclear Research)” LX-38 is a safer drug option for treating prostate issues and hair loss without hormonal side effects.
October 2025 in “Dermatology and Therapy” Ritlecitinib is being tested for effectiveness and safety in treating severe alopecia areata.
September 2002 in “Oncology Times” Promising cancer treatments were found, but the manufacturer closed.
4 citations
,
August 2014 in “Dermatology and Therapy” LOYON® is a safe and effective way to reduce cradle cap in infants and children.
October 2023 in “Naunyn-Schmiedeberg's Archives of Pharmacology” Custom software found that common allergy drugs might have new uses for various conditions and could improve survival in some cancers.
January 2023 in “Reactions Weekly” March 2023 in “Reactions Weekly” January 2023 in “Reactions Weekly” January 2023 in “Reactions Weekly” January 2025 in “Reactions Weekly” November 2024 in “Reactions Weekly” May 2023 in “Reactions Weekly” 1 citations
,
March 2026 in “American Journal of Clinical Dermatology” April 2022 in “Reactions Weekly” August 2024 in “British Journal of Dermatology” Rezpegaldesleukin shows promise for treating severe alopecia areata.
November 2015 in “Journal of the Korea Academia-Industrial cooperation Society” The new assay can help develop products for hair re-growth.
November 2025 in “SKIN The Journal of Cutaneous Medicine” Ritlecitinib 50 mg effectively promotes and sustains hair regrowth in alopecia areata patients.
March 2026 in “Brazilian Journal of Animal and Environmental Research” Deslorelin can help control reproduction and improve hair growth in German Spitz dogs.
January 2023 in “Brazilian Journal of Pharmaceutical Sciences” A method was found to accurately measure spironolactone and canrenone in blood samples using liquid chromatography-mass spectrometry.